Abstracts tagged "Inflammation"

Abstract Number: 1690 • ACR Convergence 2022
Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition
Takumi Nagamoto¹, takaichi okano², Yoshikazu Fujikawa³, Yuzuru Yamamoto², Hirotaka Yamada², Yo Ueda², Sho Sendo⁴ and Jun saegusa², ¹Kobe University, Kobe, Japan, ²Kobe University, Rheumatology, Kobe, Japan, ³Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan, ⁴University California, San Diego (UCSD), La Jolla, CA
Background/Purpose: Butyric acid is known to improve chronic inflammation such as inflammatory bowel disease and arthritis. Dendritic cells activate in inflammatory condition, migrate to regional…
Abstract Number: 1977 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Jonathan Graf¹, Martin Jacobs², Debbie Gladd-Foley³, Yelliann Ruiz-Irizarry⁴, Alan Kivitz⁵, Melvin Churchill⁶, Arash Kardan⁷, Mara Leach⁸, David Ralph⁸, Nicole Korczak⁸, Addison Hasselbach⁸, Bonnie Abbruzzese⁸, Rachael Hershey⁸, Beth Potter⁸, Jessica Fitzpatrick⁸, Aaron Thornton⁸, Michael Blue⁸ and Michael Rosol⁸, ¹Ucsf, San Francisco, CA, ²Kettering Network Radiologists, Kettering, OH, ³Premier Rheumatology of Oklahoma, Tulsa, OK, ⁴Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, ⁷Baylor College of Medicine, Department of Radiology, Houston, TX, ⁸Navidea Biopharmaceuticals, Dublin, OH
Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
Abstract Number: 0404 • ACR Convergence 2022
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
Raphael Micheroli¹, Tim Killeen², Hyejin Jo³, Kenneth Kwok³, Bassel Elzorkany⁴, Caroline Ospelt⁵, Adrian Ciurea⁶ and Michael Nissen⁷, ¹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ²Pfizer Ltd, Tadworth, Switzerland, ³Pfizer Inc, New York, NY, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland
Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
Abstract Number: 0604 • ACR Convergence 2022
Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis
Patricia Riedlova¹, Luís Almeida², Cecilia Ansalone³, Shatakshi Sood¹, Bart Everts² and Carl Goodyear¹, ¹University of Glasgow, Glasgow, Scotland, United Kingdom, ²Leiden University Medical Center, Leiden, Netherlands, ³UCSD and University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterised by synovial inflammation and joint destruction. Prior research has revealed perturbation in the myeloid compartment of…
Abstract Number: 0903 • ACR Convergence 2022
Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis
Emil Rydell¹, Lennart Jacobsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…
Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
James Krueger¹, Kilian Eyerich², Dennis McGonagle³, Carrie Greving⁴, Kacey Sachen⁴, Deepa Hammaker⁴, Phuc Bao⁴, Eilyn Lacy⁴, M. Merle Elloso⁵, Yevgeniya Orlovsky⁵, Iain B McInnes⁶ and Anne Fourie⁷, ¹The Rockefeller University, New York, NY, ²Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁷Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
Abstract Number: 1706 • ACR Convergence 2022
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
Emmanuel Abimelec Camacho-Morán¹, jiram torres-Ruiz¹, Jaquelin Lira-Luna¹, Ana Sofía Vargas-Castro², Alfredo Pérez-Fragoso¹, Miroslava Nuñez-Aguirre², Beatriz Alcalá-Carmona³, Abdiel Absalón-Aguilar³ and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Post-COVID19 syndrome has been defined as the persistence of symptoms and/or organic damage for more than three weeks after the presence of clinical infection…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 0408 • ACR Convergence 2022
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Philip C. Robinson¹, Walter P Maksymowych², Lianne Gensler³, Martin Rudwaleit⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵, Mindy Kim⁶ and Atul Deodhar⁷, ¹University of Queensland School of Clinical Medicine, Brisbane, Australia, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Smyrna, GA, ⁷Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (OSI) during the…
Abstract Number: 0608 • ACR Convergence 2022
Wnt Pathway Regulators R-spondin 3 and Dickkopf-related Protein 3 Demarcate a Transcriptional Gradient That Drives Synovial Fibroblast Inflammatory Pathology in Rheumatoid Arthritis
Alisa Mueller¹, Angela Zou², SABA NAYAR³, Emily Taylor³, Triin Major³, David H Gardner³, Gerald FM Watts¹, Adam Croft³, Roche Fibroblast Network Consortium⁴, Andrew Filer³, Christopher Buckley⁵, Kevin Wei⁶, ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴Roche, Basel, Switzerland, ⁵University of Oxford, Oxford, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Synovial fibroblasts are key players in rheumatoid arthritis (RA) where they secrete inflammatory cytokines and directly instigate cartilage and bone destruction. However, most treatments…
Abstract Number: 0978 • ACR Convergence 2022
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
Muhammad Shipa¹, liliana ribeiro santos², Dao X Nguyen¹, Andrew Embleton-Thirsk¹, Mariea parvaz¹, David Isenberg¹, Caroline Gordon³ and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²University College London, London, ³Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The results from the BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We…
Abstract Number: 1498 • ACR Convergence 2022
The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis
gavriel Balulu¹, Victoria Furer¹, Jonathan Wollman², David Levartovsky¹, Valerie Aloush¹, Ofir Elalouf¹, Hagit Sarbagil-Maman³, Liran Mendel², Sara Borok¹, Daphna Paran¹, Ori Elkayam³ and Ari Polachek¹, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA). Ultrasound (US) is considered a more accurate tool for the assessment of enthesitis compared to…
Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Angie El-Said¹, Areeb Ahmad², Massimo Valenti³, Neel K. Shah¹, Susana Soto¹ and Shazia Beg⁴, ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Sapienza University of Rome, School of Medicine, Rome, Italy, ⁴UCF, Orlando, FL
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
Abstract Number: 1993 • ACR Convergence 2022
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
Esha Lal¹, Marta Sala Climent², francesca cedola², Marta Fernandez-Bustamante³, Meritxell Agustín-Perez², Maram Alharti², Abha Singh⁴, Soo-In Choi², Tania Rivera², Katherine Nguyen⁴, Susan Lee², Aaron Armando⁵, Tiffany Holt⁶, Oswald Quehenberger⁵, Shahrokh Golshan⁶, Roxana Coras⁷ and Monica Guma⁸, ¹Department of Medicine, School of Medicine, University of California, San Diego, San Diego, ²Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, ³Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, ⁴University of California, San Diego, San Diego, CA, ⁵Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, ⁶Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, ⁷University of California San Diego, San Diego, CA, ⁸UCSD, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
Abstract Number: 0019 • ACR Convergence 2022
Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age
Meaghan Holub¹, Amanda Wahhab², Joseph Rouse², Brandon Jutras³, Klemen Strle⁴, Adam Edelstein⁵ and Robert Lochhead⁶, ¹Central Michigan University College of Medicine, Mount Pleasant, MI, ²Medical College of Wisconsin, Milwaukee, WI, ³Virginia Tech, Blacksburg, VA, ⁴Wadsworth Center, Albany, NY, ⁵Northwestern Medicine, Chicago, IL, ⁶Medical College of Wisconsin, Germantown, WI
Background/Purpose: Peptidoglycan (PG) is a bacterial cell wall component that is known to induce innate immune responses. PG has been identified as a driver of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].